Ferring Pharmaceuticals

Press Release

Monroe Resident Wins Honorable Mention Prize for Ferring’s My Little Miracle Essay Contest

Pictured: David Reese Callicott, 19-month-old son of Lisa Callicott, honorable mention winner of Ferring Pharmaceutical’s My Little Miracle Essay Contest. Lisa’s $1,000 prize will be placed in a 529 education fund for David’s future education. David was born with the help of Bravelle™ (urofollitropin for injection, purified) – one of Ferring’s fertility treatments.

Monroe, LA – December 9, 2004 – Lisa Callicott of Monroe received a $1,000 honorable mention prize from Ferring Pharmaceuticals for her entry in the Company’s My Little Miracle Essay Contest. Lisa’s entry, Our Miraculous Story, chronicled the long path to her son’s birth. The prize money will be deposited into an education fund for David Reese, her 19-month-old son born with the help of Bravelle™ (urofollitropin for injection, purified) – one of Ferring’s fertility treatments.

“We have been blessed now by Ferring for a third time! The first two, and most important, were the help they provided in conceiving our two sons. With Ferring’s help, we are expecting the birth of our second son in late March of 2005,” said Lisa Callicott. “And we are also thrilled to start this education fund for David and we thank Ferring for their contribution. Our lives have been forever changed thanks to Ferring and our physician – Dr. Dunn.”

“We are delighted to offer this program to help fertility patients contribute to their children’s future,” said Wayne Anderson, president, Ferring Pharmaceuticals. “Ferring is committed to providing patients with safe, effective and affordable fertility treatments. This program is an extension of Ferring’s support of its patients.”

The My Little Miracle Essay Contest celebrated the births of children made possible through Ferring’s fertility treatments, Bravelle™ (urofollitropin for injection, purified) and Repronex™ (menotropins for injection, USP). Ferring awarded $25,000 in education funds to 12 winners from around the country.

About the Callicotts, their First Miracle, and their Miracle to come…

The Callicotts met in college thirteen years ago. When married, they began trying to conceive almost immediately. After a year and a half of unsuccessfully trying to conceive on their own, the Callicotts sought help. The couple felt restricted in their treatment options since their insurance would not cover all of the medications that their physician, Dr. Randall Dunn, Obstetrical and Gynecological Associates, P.A., of Houston, Texas, wanted to prescribe. After several failed attempts and despite the lack of insurance coverage for certain medications, the Callicotts decided to try one cycle with the help of Bravelle™. In her essay, Lisa speaks of her experience:

On August 14th, we got the call – we were pregnant!! We found out quickly [that] it was only one baby and everything proceeded as normal. … On the 102nd month of trying, Bravelle™, on the first try, helped me conceive! On April 10, 2003, our beautiful son, David Reese, was born. Our wonderful story doesn’t stop there! In the spring of 2004 … we decided to try for a second baby. We only had the funds to try one time and in July 2004 we did a round of Bravelle™. You could have knocked me over with a feather when the doctor’s office called to say I was pregnant. Out of nine+ years of trying to conceive, with only two cycles of Bravelle™, I had TWO successful pregnancies!! We have yet to meet our latest miracle, but know that he/she will be another blessing … Looking back, I can hardly remember the years of tears and heartache that passed. I cannot explain how the birth of David erased all those painful memories.

With the help of Bravelle™, Lisa and her husband Rob are expecting their second child in late March 2005.

**About Bravelle™ and Repronex™**

Bravelle™ (urofollitropin for injection, purified), a highly purified human-derived follicle-stimulating hormone (hFSH) for infertility treatment, contains 75 IU of FSH and up to two percent LH activity. Bravelle™, administered SC or IM in conjunction with hCG, is indicated for ovulation induction following pituitary suppression. Bravelle™, administered SC in conjunction with hCG, is also indicated for multiple follicular development during ART cycles in patients who have previously received pituitary suppression.

Repronex™ (menotropins for injection, USP) is the only human menopausal gonadotropin (hMG) on the market in the U.S. and is approved for both subcutaneous and intramuscular administration.

Bravelle™ and Repronex™, like all gonadotropins, are potent substances capable of causing mild to severe adverse reactions, including ovarian hyperstimulation syndrome (OHSS) (incidence of 6.0% and 3.5%, respectively), with or without pulmonary or vascular complications, in women undergoing therapy for infertility.

Both treatments are marketed by Ferring Pharmaceuticals Inc., a world leader in naturally occurring protein hormones. Only physicians thoroughly familiar with infertility treatment, including the risk of multiple births and adverse reactions, should prescribe these medications. Like other products for ovarian stimulation, treatment with Repronex™ and/ or Bravelle™ may result in multiple gestations.

About Ferring Pharmaceuticals

Ferring Pharmaceuticals, part of the Ferring Group, a privately owned, international pharmaceutical company, markets Bravelle™, Repronex™ and Novarel™ (chorionic gonadotropin for injection, USP) in the U.S. to infertility specialists and their patients. The Ferring Group specializes in the research, development and commercialization of compounds in general and pediatric endocrinology, urology, gastroenterology, obstetrics/gynecology and infertility. For more information, call 888-337-7464 or visit www.ferringusa.com or www.ferringfertility.com.

# # #

For full prescribing information for Bravelle™ and/ or Repronex™, please contact Kelly Laban.